Evidence Review
The Foundational Animal and Human Pilot Study (Brandhorst et al., 2015)
Brandhorst and colleagues at USC published the defining paper on the FMD in Cell Metabolism in 2015 [1]. In mice, repeated FMD cycles (equivalent to 5-day monthly cycles scaled to mouse lifespan) produced significant benefits: reduced abdominal fat, improved cognitive performance on maze tests, improved immune function, and extension of median lifespan by 11%. Visceral fat reduction was particularly notable.
The paper also included a small human pilot (n=19) that documented reductions in IGF-1, glucose, blood pressure, and cholesterol, with no serious adverse events. This pilot formed the basis for the larger trial that followed.
The First Human Randomised Controlled Trial (Wei et al., 2017)
Wei and colleagues randomised 100 generally healthy adults to either three monthly FMD cycles or an unrestricted diet control group, then allowed the control group to cross over to FMD for three more months [2]. Published in Science Translational Medicine, this remains the most cited FMD clinical trial.
Key findings after three FMD cycles:
- IGF-1 reduced by 15% (from ~170 to ~145 ng/mL)
- Body weight reduced by 2.6 kg, with trunk fat showing larger reductions than lean mass
- Systolic blood pressure reduced by approximately 4 mmHg
- Fasting glucose, total cholesterol, triglycerides, and CRP all showed improvement — particularly in participants who were at higher risk at baseline
Effects were largely maintained at a follow-up assessment conducted after participants resumed normal eating. The specificity of the response to baseline risk status is important: participants with normal values at the start showed little change, while those with elevated markers saw meaningful improvements. This suggests the FMD is correcting dysfunction rather than optimising from an already-healthy baseline.
No serious adverse effects were reported, though some participants experienced mild fatigue and headache during the five days — consistent with what is seen in other calorie-restricted protocols.
Autoimmunity and Neurological Applications (Choi et al., 2016)
A separate clinical study tested the FMD in patients with relapsing-remitting multiple sclerosis (MS), comparing it to a Mediterranean diet and a ketogenic diet [3]. Published in Cell Reports, the FMD group showed improvements in quality of life measures, reduced fatigue, and shifts in immune cell populations consistent with reduced autoimmune activity.
Mouse MS models (experimental autoimmune encephalomyelitis) showed even more dramatic effects: FMD cycles reduced disease severity and promoted remyelination — the repair of the myelin sheath around nerve fibres. The mechanism proposed involves regulatory T cell expansion and oligodendrocyte precursor cell regeneration during refeeding. While the human data from this study is preliminary, it opens a meaningful research direction for dietary management of autoimmune conditions.
Biological Age Reduction (Brandhorst et al., 2024)
A 2024 paper in Nature Communications applied epigenetic aging clocks to blood and liver marker data from FMD participants and reported that three FMD cycles were associated with markers consistent with a 2.5-year reduction in biological age [4]. The analysis used both hepatic markers and established DNA methylation-based aging algorithms.
The authors were careful to note that this is an indirect measurement — blood marker proxies for biological age rather than direct epigenetic clock assessment — and that larger long-term trials are needed. Still, the consistency of the direction of effect across multiple aging-related biomarkers is notable.
Type 2 Diabetes: Primary Care RCT (de Groot et al., 2024)
Published in Diabetologia, this 12-month randomised trial integrated a monthly FMD programme into routine primary care for patients with type 2 diabetes managed by metformin and/or diet alone [5]. Participants in the FMD group achieved:
- Reduced medication requirement in 53% of FMD participants vs. 8% of controls (p<0.001)
- HbA1c improvement despite reduction in medication
- Body weight reduction of 3.6 kg versus controls
The finding that glycaemic control improved even as medication was reduced is clinically significant. It suggests the FMD was producing real metabolic change rather than simply compensating for medication effects. Glycaemic management deteriorated in 59% of control participants over 12 months versus 23% in the FMD group — highlighting the progressive nature of type 2 diabetes when left to standard care alone.
Strength of Evidence
The FMD has an unusually strong evidence base for a dietary intervention: multiple mechanism-confirmed animal studies, at least two randomised human trials with hundreds of participants, and replication across different disease states. The largest uncertainties are long-term (beyond 12 months) adherence and safety data, optimal cycling frequency for maintenance versus therapeutic phases, and whether DIY versions can match the macronutrient precision of the validated protocol. The autoimmune and cancer-adjacent applications are promising but need larger dedicated trials before clinical recommendations can be made.